Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 25, 2008. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility under the Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction notifications.
Material Changes
There are no material changes to financial performance or operations reported in this filing. The only reported activity is an increase in shareholdings by specific individuals due to dividend reinvestment.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It strictly details the reinvestment of dividends paid on April 10, 2008, into Ordinary shares at a price of GBP11.01 per share.
Important Facts for Investors
- Transaction Type: Increase in share interests via dividend reinvestment under the GlaxoSmithKline Annual Investment Plan.
- Share Price: GBP11.01 per share.
- Dividend Date: April 10, 2008.
- Notified Individuals: Dr M M Slaoui (319 shares), Mr M Dunoyer (154 shares), Mr D Learmouth (27 shares), Dr D Pulman (235 shares), and Mr A P Witty (143 shares).
- Financial Data: No financial performance data is included in this specific filing.